NanoViricides Presents NV-387 as Leading Antiviral Defense

NanoViricides, led by Dr. Anil Diwan, highlights NV-387, a broad-spectrum antiviral drug, as key in combating emerging COVID and Bird Flu variants. The new COVID variant, Nimbus, is spreading swiftly, with enhanced transmissibility and resistance to past vaccines. Meanwhile, certain forms of the H5N1 Bird Flu, notably those identified in the USA and Cambodia, indicate potential for high human morbidity.

NV-387 has shown superior efficacy over existing treatments like Tamiflu and Remdesivir, outperforming them in animal models. Crucially, NV-387 targets virus attachment mechanisms that remain stable despite viral mutations. This reduces the risk of resistance.

The drug is orally administered and has completed Phase I trials with favorable safety outcomes. It is positioned as a promising option for pandemic preparedness, offering manufacturing and stocking advantages over traditional vaccines.